Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson's disease: a systematic review and meta-analysis of randomized controlled trials by Skapinakis, Petros et al.
Skapinakis et al. BMC Neurology 2010, 10:49
http://www.biomedcentral.com/1471-2377/10/49
Open Access RESEARCH ARTICLE
© 2010 Skapinakis et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduc-
tion in any medium, provided the original work is properly cited.
Research article Efficacy and acceptability of selective serotonin 
reuptake inhibitors for the treatment of depression 
in Parkinson's disease: a systematic review and 
meta-analysis of randomized controlled trials
Petros Skapinakis*1,2, Eleni Bakola1, Georgia Salanti3, Glyn Lewis2, Athanasios P Kyritsis4 and Venetsanos Mavreas1
Abstract
Background: Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants for 
the treatment of depression in patients with Parkinson's Disease (PD) but data on their efficacy are controversial.
Methods: We conducted a systematic review and meta-analysis of randomized controlled trials to investigate the 
efficacy and acceptability of SSRIs in the treatment of depression in PD.
Results: Ten studies were included. In the comparison between SSRIs and Placebo (n = 6 studies), the combined risk 
ratio (random effects) was 1.08 (95% confidence interval: 0.77 - 1.55, p = 0.67). In the comparison between SSRIs and 
Tricyclic Antidepressants (TCAs) (n = 3 studies) the combined risk ratio was 0.75 (0.39 - 1.42, p = 0.37). An acceptability 
analysis showed that SSRIs were generally well tolerated.
Conclusions: These results suggest that there is insufficient evidence to reject the null hypothesis of no differences in 
efficacy between SSRIs and placebo in the treatment of depression in PD. Due to the limited number of studies and the 
small sample sizes a type II error (false negative) cannot be excluded. The comparison between SSRIs and TCAs is based 
on only three studies and further trials with more pragmatic design are needed.
Background
Major depressive disorder is common among patients
with Parkinson's disease (PD). A recent systematic review
reported that the prevalence of depression may range
from 8% in community-based patients to more than 20%
in outpatient or inpatient settings, while depressive
symptoms are even more common [1]. The impact of
depression in the quality of life of patients with PD has
been recently recognized even in community-based
patients and is independent of disease severity and other
clinical or demographic variables [2,3]. Depression is also
associated with increased mortality in PD patients [4] and
is the most important risk factor for suicide especially
after neurosurgical treatment of PD [5]. Thus, recogniz-
ing and treating depression in the context of PD is impor-
tant to reduce disability and improve prognosis.
Treatment of depression with antidepressant drugs is
well established. In the last 20 years use of antidepressant
has risen mainly due to the introduction of the selective
serotonin reuptake inhibitors [SSRIs). These drugs are
now the most commonly prescribed antidepressants in
patients with depression in general [6]. Regarding depres-
sion in the context of PD, a recent survey in the U.S.
showed that 63% of the prescriptions for depression in
PD were for SSRIs and only 7.5% for tricyclic antidepres-
sants (TCAs) [7]. The preference of SSRIs over the older
TCAs is supposedly based on their similar efficacy but
better tolerability, especially when compared with ter-
tiary amines, such as amitriptyline or imipramine [8].
Treatment of depression in the context of PD (and
other medical illnesses) poses, however, particular prob-
lems: a) most antidepressant trials exclude patients with
comorbid medical illnesses and therefore their results
cannot be generalized to these patients, b) diagnosis and
assessment of severity of depression in patients with PD
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may be more difficult because of overlapping symptoms
and the use of depression rating scales that were not spe-
cifically designed to assess depression in this context [9],
c) trials that specifically aim to investigate the efficacy of
antidepressants in depression comorbid with a medical
illness are usually carried out by independent researchers
and often are small and based on single centres.
Given these difficulties it is important to systematically
review all available evidence regarding the efficacy of
SSRIs in depression in the context of PD and if possible to
carry out a quantitative synthesis. Previous meta-analyses
of the efficacy of antidepressants in the context of PD did
not specifically focus on SSRIs [10-12]. Moreover, even
the most recent meta-analysis [13] only included two
SSRI trials with the latest being published in 2003 [14].
This review concluded that SSRIs were associated with a
negligible effect size of 0.05 compared to placebo [95%
confidence interval: -0.64, 0.75) but this result was only
based on 32 randomized patients and the analysis was
clearly underpowered for such a comparison [13]. Since
then, several new trials have been published comparing
SSRIs with placebo or other comparator interventions
and a new meta-analysis is justified given the small sam-
ple size of most trials.
The aim of this paper was therefore to systematically
review all randomized controlled trials that studied the
efficacy of SSRIs in treating depression in the context of
PD. Our primary aim was to compare the antidepressant
response in SSRIs versus placebo by carrying out a meta-
analysis of all randomized trials. A secondary aim was to
compare SSRIs versus TCAs if the number of trials iden-
tified would allow such a comparison. We finally aimed to
examine the safety and tolerability of the use of SSRIs in
this patient group.
Methods
Search strategy
We searched PubMed for English and non-English medi-
cal literature published from 1966 to December 2008. We
supplemented this source by also searching EMBASE
(1980 - 2008), the Cochrane Controlled Trials Register
(2008, issue 4) and the PsiTri database http://psi-
tri.stakes.fi/. We also searched for trials in progress or
completed in http://www.clinicalTrials.gov. We manually
checked the reference lists of prior reviews, systematic
reviews and trials.
We used the following search string (string 1) in
PubMed: (serotonin uptake inhibitors OR SSRI* OR cit-
alopram OR escitalopram OR paroxetine OR fluvoxam-
ine OR fluoxetine OR sertraline OR clomipramine OR
venlafaxine OR duloxetine) AND (parkinson* OR parkin-
soni*). Because the use of the MeSH terms does not
return records that have been supplied by the publishers
or are in the process of indexing, we also used the follow-
ing sensitive string (string 2) to identify new studies not
yet officially indexed: (serotonin inhibit* OR SSRI* OR
citalopram OR escitalopram OR paroxetine OR fluvox-
amine OR fluoxetine OR sertraline OR clomipramine OR
venlafaxine OR duloxetine) AND (parkinson* OR parkin-
soni*) AND (publisher [sb] OR (in process [sb])).
Additional strategy for identifying trials included
searching the reference list of the retrieved studies.
Inclusion and exclusion criteria
Studies included in our systematic review were required
to meet all the following criteria:
• Study design: randomised controlled trial.
• Participants: Study participants were required to 
have a clinical diagnosis of idiopathic Parkinson's dis-
ease and also a clinical diagnosis of depression (as 
defined by the authors of the trials). Both gender and 
all ages are included.
• Pharmacological intervention: Included studies 
were required to have at least one arm in which an 
SSRI was given as the main treatment. Acceptable 
comparator groups included placebo or other antide-
pressant treatment such as other antidepressant med-
ications or other biological or psychological 
treatments (e.g. electroconvulsive therapy, repetitive 
transcranial magnetic stimulation (rTMS) or cogni-
tive behavioural therapy).
• Outcome measurement: assessment of the change 
in the score of the depression rating scale used in each 
study and/or assessment of the response to the treat-
ment as defined in each study.
W e excluded studies from our review if they met the
following criterion:
• Depression was not assessed with a validated instru-
ment (e.g. Hamilton Depression Rating Scale, Beck 
Depression Inventory e.t.c.).
In addition to these criteria, in our quantitative synthe-
sis (meta-analysis) we also excluded studies that met the
following criteria:
• The study did not report a binary outcome 
(response vs non-response) or such an outcome was 
not possible to be extracted from the paper or by 
directly contacting the authors of the study.
• The comparator was not placebo or a drug officially 
licensed for the treatment of depression.
Data extraction, outcome measurement and assessment of 
methodological quality
Data extracted included information on:
a) the authors, the country, the publication year;
b) patients (age, sex, depression diagnosis, PD 
diagnosis, duration and stage of PD);
c) methods (study design, depression scale used, 
definition of treatment response, duration of 
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d) interventions (type and dose of SSRI used, type 
and/or dose of the control intervention);
e) outcomes and results (number of patients 
entering and completing the study, number and 
reasons for dropouts and withdrawals, number of 
patients responding in active and control arms).
Our primary outcome measure was the number of
patients in each treatment group who responded to treat-
ment. Response was defined as the proportion of patients
who had a reduction of at least 50% from the baseline
score on the Hamilton Depression Rating Scale (HDRS)
or the Montgomery-Åsberg Depression Rating Scale
(MADRS) or who scored much or very much improved in
the Clinical Global Impression Scale (CGI). When a trial
had reported results from several scales, we used the
HDRS as the first choice, followed by MADRS and CGI.
We used the dichotomous response as our primary out-
come and not reduction in the severity of symptoms mea-
sured as a continuous outcome, because we think that
results are more readily interpretable from a clinical per-
spective. Although, the focus of this review was the effi-
cacy of SSRIs, we also measured the total number of
dropouts in each arm to assess the acceptability of these
drugs in Parkinson's disease patients with depression.
Data extraction was performed independently by two
of the authors (PS, EB) and checked by another (VM). In
case of disagreement two senior authors (PS, VM)
reviewed the studies and reached a consensus.
To assess the methodological quality of included trials
we used the criteria for quality assessment recommended
by the Cochrane Collaboration Handbook [15] which are
mainly focused on descriptions of sequence generation,
allocation concealment, blinding, completeness of out-
come data, selective outcome reporting and other poten-
tial sources of bias.
Statistical Analysis
Data from the data sheets were entered into Review Man-
ager version 4.2 [16] by two investigators using the dupli-
cate data entry facility of the software. Number of
respondents in each study were recorded according to the
intention to treat principle and this was based on the total
number of patients randomized to each treatment. For
the quantitative synthesis and the generation of forest
plots we also used "Comprehensive meta-analysis" ver-
sion 2.0 http://www.meta-analysis.com. Using the latter
we calculated risk ratios for antidepressant response
(ratios of the number of patients who responded divided
by the number of patients initially randomized to the
respective group) and their 95% confidence intervals.
Risk ratios greater than 1 indicate a better response for
the SSRI group. To investigate the degree of between-trial
heterogeneity we used the Q and I-squared statistics [17].
In the presence of significant heterogeneity the potential
sources were investigated (type of antidepressant, patient
characteristics, study quality). As we anticipated that
most of the included studies would have small sample
sizes we did not base our choice of modelling upon the
heterogeneity statistics. Instead, the random effects
model was a priori selected to combine risk ratios as this
method is more robust and has better external generalis-
ability. Our primary research interest was to compare the
efficacy of SSRIs as a class versus placebo. Our secondary
aim was to compare the efficacy of SSRIs versus TCAs if
the number of trials and sample size would allow such a
comparison. Side effects are presented in a descriptive
way but we additionally extracted the total number of
those who dropped out of the study for any reason
(including those who left due to side effects) from each
study and we present this analysis in the text. We used the
total number of dropouts and not the number of drop-
outs due to side effects because of the small sample size.
Results
Search strategy results
The results of our search strategy are presented in Figure
1. A total of 412 potentially relevant articles were identi-
fied according to our search strategy and other sources
(reference list of previous systematic reviews or retrieved
papers). We excluded 388 papers because they were
reviews, letters or irrelevant to the study aims. We
retrieved the full text of 24 articles for a more detailed
evaluation and 14 of them were excluded: 13 studies were
uncontrolled; one study - [18] - randomized PD patients
to citalopram or placebo only if they were non-depressed
while the depressed participants did not have a control
Figure 1 Flow diagram of the Study.S
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Table 1: Characteristics of the randomized controlled trials included in the systematic review and meta-analysis
Study/Country SSRI/dosage Comparator N (% male) Mean age (age 
range or SD)
Duration of 
study
Mean 
duration 
of PD (SD)
Hoehn and Yahr 
stage mean (SD)
Depressi
on Scale
Treatment responders 
(response rate)
Dropouts
Devos et al. 
(2008)/France 
[22]
citalopram (20 
mg/day)
1. placebo 2. 
desipramine (75 
mg/day)
48 (NA) 61.8 (56-68) 4 weeks 8 years NA MADRS citalopram: 8/15 (53%) 
placebo: 4/16 (25%) 
desipramine: 11/17 (65%)
3
Wermuth et al. 
(1998)/
Denmark [21]
citalopram (10-20 
mg/day)
placebo 37 (43%) 64 (44-79) 6 weeks 
(acute phase)
NA I-III (range) HDRS citalopram: 2/18 (11%) 
placebo: 3/19 (16%)
7
Antonini et al. 
(2006)/Italy [19]
sertraline (50 mg/
day)
amitriptyline 
(25 mg/day)
31 (45%) S: 71.8 (6.5) a C: 
68.5 (6.6) a
12 weeks S: 7.5 years 
(3.4) a C: 7.3 
years (4.5) a
S: 2.0 ( 0.7) a C: 2.4 
(0.6) a
HDRS sertraline: 10/16 (63%) 
amitriptyline: 8/15 (53%)
8
Barone et al. 
(2006)/Italy [20]
sertraline (mean 
dose: 48.1 ± 5.9 
mg/day)
pramipexole 
(mean dose: 
3.24 ± 1.3 mg/
day)
67 (52%) S: 68.1 (6.5) C: 
64.8 (8.3)
12 weeks NA S: 2.5 (median) C: 
2 (median)
HDRS sertraline: 16/34 (47%) 
pramipexole: 23/33 (70%)
8
Leentjens et al. 
(2003)/The 
Netherlands 
[14]
sertraline (25-100 
mg/day)
placebo 12 (67%) 67 (7.8) 10 weeks NA I-IV (range) MADRS sertraline: 3/6 (50%) placebo: 
4/6 (67%)
0
Fregni et al. 
(2004)/USA [25]
fluoxetine (20 mg/
day)
rTMS (15 Hz) 43 (62%) a S: 66.0 (8.5) a C: 
65.3 (7.8) a
8 weeks NA S: 2.1 (1.2) a C: 2.1 
(1.2) a
HDRS fluoxetine: 9/21 (43%) rTMS: 
9/22 (41%)
1
Serrano-
Duenas (2002)/
Ecuador [23]
fluoxetine (mean 
dose: 27.3 mg/
day)
amitriptyline 
(mean dose: 
35.2 mg/day)
77 (56%) 68.2 (4.5) 12 months 6.9 years 
(0.8)
II HDRS NA 19
Avila et al. 
(2003)/Spain 
[24]
fluoxetine (mean 
dose: 25 mg/day)
nefazodone 
(mean dose: 200 
mg/day)
16 (44%) 70.4 (59-78) 12 weeks 5 years S: 2.6 (0.8) C: 2.3 
(0.5)
BDI NA 3
Menza et al. 
(2008)/USA [26]
paroxetine CR 
(mean dose: 28.4 
mg/day)
1. placebo 2. 
nortriptyline 
(mean dose: 
48.5 mg/day)
52 (52%) 62.2 (8.7) 8 weeks 6.6 years 2.2 HDRS paroxetine: 2/18 (11%) 
placebo: 4/17 (24%) 
nortriptyline 9/17 (53%)
18
Rabey et al. 
(1996)/Israel 
[27]
fluvoxamine 
(mean dose: 78 
mg/day)
amitriptyline 
(mean dose: 69 
mg/day)
47 (NA) 75 (NA) 16 weeks 7 years NA HDRS fluvoxamine: 12/20 (60%) 
amitriptyline: 15/27 (56%)
20
PD: Parkinson's disease; MADRS: Montgomery-Asberg Depression Rating Scale; HDRS: Hamilton Depression Rating Scale; BDI: Beck Depression Inventory S: SSRI- group; C: comparator-group; rTMS: 
repetitive transcranial magnetic stimulation; SD: standard deviation; NA: not available
a Demented patients are excluded; b available data only for completeSkapinakis et al. BMC Neurology 2010, 10:49
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group (see Additional file 1 Table s1 for a list of studies
excluded from the review). Finally 10 studies were
included in the review.
Description of studies
The characteristics of the ten trials are summarized in
table 1. These trials included three sertraline studies (10
to 12 week duration) [14,19,20], two citalopram studies (4
to 6 week duration) [21,22], three fluoxetine studies (8
weeks to 3 months duration) [23-25], one paroxetine
study (8 weeks duration) [26] and one fluvoxamine study
(16 week duration) [27].
The mean age of the participants was over 65 years for
the majority of the studies. In most studies participants
were diagnosed with idiopathic Parkinson's disease
according to the United Kingdom's Parkinson's Disease
Society Brain Bank (UK-PDS-BB). In most studies
depression was diagnosed according to Diagnostic and
Statistical Manual of Mental Disorders 3rd revised or 4th
edition (DSM-III-R or DSM-IV) criteria [28]. Five studies
included patients with major depression only [14,19-22],
one study enrolled patients with major or minor depres-
sion [25], two studies included patients with major
depression or dysthymic disorder [24,26] and two studies
included patients with a depression diagnosis without
specifying further [23,27].
In studies that used a dichotomous outcome (response)
this was defined as an at least 50% reduction from the
baseline score in the depression scale used. Most studies
used the Hamilton Depression Rating Scale (HDRS) to
assess the severity of depression and treatment response
[19-21,23,25-27]. Mean baseline scores of the HDRS were
between 19-21 for most of the studies, corresponding to
moderate depression. One study [25] had baseline scores
of more than 25, indicating severe depression and one
study had unusually high scores >40 [23]. Montgomery-
Åsberg Depression Rating Scale (MADRS) was used in
two studies [14,22], with mean baseline scores of 19-20 in
one study [14] and a median of >25 in the second study
[22]. Other assessment tools for depression included
Beck Depression Inventory (BDI) [24,25], Melancholia
Scale (MES) [21] and Zung-Self Rating Depression Scale
(SDS) [20]. Clinical Global Impression Scale (CGI) was
additionally used in three studies [21,24,26]. For the neu-
rological evaluation of the participants the studies used
Hoehn and Yahr scale [14,19-21,23-26,29] and Unified
Parkinson's Disease Rating Scale (UPDRS) [14,19-26,30].
Quality of life was assessed in three studies: one used
the 39-item Parkinson's Disease Questionnaire (PDQ-39)
[19], another its short form (PDQ-8) [26] and two studies
used the 36-item Short Form Health Survey (SF-36)
[20,26].
The cognitive status of the participants was assessed in
most studies with the Mini Mental State Examination.
Demented patients were excluded from eight studies
[14,19,21-26].
In most studies adverse effects were reported spontane-
ously and verbally to the investigators or via question-
naires. In three studies the authors used the "Udvalg for
Kliniske Undersogelser" side effects rating scale (UKU)
[31,21,24,25]. All drug treatments were generally well tol-
erated. Common side effects for the SSRIs group
Figure 2 Risk Ratio for response of SSRIs vs Placebo in Parkinson's Disease Patients.Skapinakis et al. BMC Neurology 2010, 10:49
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included nausea, fatigue/asthenia and diarrhoea and for
the TCA group dry mouth, somnolence, constipation and
orthostatic hypotension.
Overall 192 patients were randomised to an SSRI (65 to
fluoxetine, 56 to sertraline, 33 to citalopram, 20 to fluvox-
amine and 18 to paroxetine), and 238 to a comparator
group (58 patients to placebo, 83 patients to amitrip-
tyline, 17 to desipramine, 17 to nortriptyline and 64 to
other treatments including pramipexole, nefazodone and
rTMS). In total 430 patients were enrolled in the studies.
There were 343 patients who completed the studies
(overall completion rate 80%). A detailed narrative
description of the studies, including assessment of meth-
odological quality and reporting of common side-effects,
is given in additional file 2.
Meta-analysis results
a) Comparison 1: SSRIs versus Placebo
Four trials had a separate placebo arm: two citalopram
studies [21,22], one sertraline study [14] and one parox-
etine study [26]. The Wermuth et al. study [21] did not
report the dichotomous response but we obtained the
data after contacting the authors (Dr Wermuth).
Since this comparison was the main aim of the analysis,
in order to use all possible available evidence we also con-
sidered the inclusion in the meta-analysis of the following
two studies:
a) the study by Antonini et al. [19] compared standard 
dose sertraline to a very low dose of amitriptyline (25 
mg/day). This dose is not normally considered as hav-
ing antidepressant potency and a meta-analysis of the 
efficacy of low versus standard dose amitriptyline 
generally identified papers with doses not less than 
37.5 mg/day [32]. Therefore one can consider this 
dose as an active placebo with the added advantage of 
a diminished unblinding effect [33]. Inclusion of this 
sertraline trial in the analysis would result in the 
increase of the number of patients randomized to ser-
traline from the 6 included in the Leentjens et al. 
study [14] to 22 as 16 patients in the Antonini et al. 
study [19] were randomized to this treatment.
b) the study by Fregni et al. [25] compared fluoxetine 
plus sham rTMS with placebo plus rTMS (total N = 
43). Given that rTMS is still considered as experimen-
tal in the treatment of depression and a systematic 
review found insufficient evidence to support its use 
in depression [34], we also considered this study as a 
predominantly SSRI vs placebo comparison. In any 
case we have repeated the analyses after excluding the 
two additional studies for comparison.
Treatment response was assessed using the HDRS in
four studies [19,21,25,26] and the MADRS in two studies
[14,22]. Figure 2 shows the results of our full analysis with
six studies and 189 patients included. The observed
response rate for SSRIs was 36% and that of placebo 34%.
The combined risk ratio (random effects) was 1.08 and
the 95% confidence interval was 0.75 to 1.55 (p = 0.67).
Statistical tests did not show significant heterogeneity (Q
= 3.82 with 5 degrees of freedom, p = 0.57). Exploration
of the forest plot shows that one study, Devos et al. [22], is
the only study with a trend for a favorable response for
SSRIs (citalopram) with a risk ratio of 2.13 and 95% CI
0.81 - 5.64 (p = 0.13). Pooling, however, the two available
citalopram studies [21,22] reduced the risk ratio for cit-
alopram to 1.52 (95% CI 0.55 - 4.17, p = 0.42). Excluding
the Antonini et al. [19] and Fregni et al. [25] studies, the
results were not different with the combined risk ratio
closer to unity than before (risk ratio = 0.99, 95% CI of
0.51 to 1.95, p = 0.98).
A funnel plot is presented in figure 3. It can be seen that
small trials with negative results have been published but
small trials with positive results are missing. Publication
bias is more likely when small negative trials are missing
and this is not the case here. It should be noted, however,
that for a more accurate assessment of publication bias a
larger number of studies is usually needed.
Since the results were negative we also tested whether
the use of the continuous outcome (standardized mean
differences of the endpoint scores on the HDRS or
MADRS) would make any difference compared to the
dichotomous response. One study [22] was excluded
from this analysis because due to non-normal data the
authors reported medians and quartiles only. For the
remaining five studies, the standardized mean difference
using the Hedges' g estimate was -0.13 (95% CI: -0.43 -
0.17, p = 0.40) with no evidence of heterogeneity (Q =
2.71 with 4 degrees of freedom, p = 0.61). Details of this
analysis and a forest plot are provided in additional file 3.
b) Comparison 2: SSRIs versus TCAs
Five studies had used an older TCA as the comparator:
three amitriptyline studies [19,23,27] one desipramine
study [22] and one nortriptyline study [26]. As explained
in the previous section the Antonini et al. study [19] used
a very low dose of amitriptyline and was excluded from
this analysis. Moreover, the Serrano-Duenas study [23]
had several methodological limitations with high risk of
bias which made its inclusion problematic (no reporting
of binary outcome, CONSORT guidelines were not fol-
lowed, there is no flow chart of the randomization pro-
cess, there is no information on eligibility criteria,
potential unblinding problems since the SSRI was given
in the morning and amitriptyline at night). Since the
study did not report a binary outcome we decided not to
include it in the meta-analysis. Therefore, for this analysis
we included three studies. It should be noted however ,
that one of the studies [27] is only in abstract form and
was never published as a full paper.Skapinakis et al. BMC Neurology 2010, 10:49
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Treatment response was assessed using the HDRS in
two studies [26,27] and the MADRS in one study [22].
Figure 4 shows the results of this analysis with three stud-
ies included (total N = 114). The observed response rate
for SSRIs was 41% and that of TCAs 57%. The combined
risk ratio (random effects) was 0.75 with the 95% CI 0.39 -
1.42 (p = 0.37).
c) Acceptability Analysis
We first compared total dropouts in SSRIs vs. placebo.
Five studies were included in this analysis as one small
study had no dropouts. 17 out of 88 patients on SSRI
dropped out (19.3%) vs. 12 out of 89 on placebo (13.5%).
The combined risk ratio for dropouts was 1.28 with a 95%
CI of 0.67 - 2.45 (figure 5). It should be noted that citalo-
Figure 4 Risk Ratio for response of SSRIs vs TCAs in Parkinson's Disease Patients.
Figure 3 Publication Bias in SSRIs vs Placebo trials of depression in PD.Skapinakis et al. BMC Neurology 2010, 10:49
http://www.biomedcentral.com/1471-2377/10/49
Page 8 of 11
pram showed a greater tendency for increased dropout
rates but this result was based on only two studies (com-
bined risk ratio for citalopram 3.05, 95% CI 0.80 - 11.68, p
= 0.10).
In the three studies that compared SSRIs with TCAs
and were included in the efficacy analysis, the dropouts
did not differ between the two classes of drugs (30% for
SSRIs vs 31% for TCAs). The combined risk ratio was
0.96 with a 95% CI of 0.56 - 1.64 (p = 0.88).
A more detailed description of the side effects reported
in each study is given in the additional file 2.
Discussion
Main Findings
In the present meta-analysis there was insufficient evi-
dence to reject the null hypothesis of no treatment differ-
ences between SSRIs and placebo in the treatment of
depression in the context of PD. The crude response rate
in SSRIs was 36% versus 34% in placebo and the com-
bined risk ratio (random effects) was 1.08 (95% CI 0.77 -
1.55). The comparison of SSRIs with TCAs was based on
only three studies, one of them only published in abstract
form, and the risk ratio was 0.75 (0.39 - 1.42) with a crude
response rate of 41% vs. 57%.
Limitations
Several limitations of this study should be considered.
F i r s t,  t h i s  a n a l y s i s  i n c l u d e d  a  l i m i t e d  n u m be r  o f  s m a l l
studies and therefore type-II errors (i.e. false negative
results) due to chance cannot be entirely excluded as an
alternative explanation for our main finding. This issue is
even more important regarding specific antidepressants.
Therefore we cannot exclude the possibility that specific
SSRIs may in the future show evidence of superiority
compared to placebo. Second, patients included in the
trials are not always representative of the patients seen in
real clinical practice. Most trials excluded patients with
dementia; severe motor fluctuations; comorbid medical
disorders; and symptoms of psychotic depression. There-
fore, our results should not be generalized in such
patients. Third, we selected to use as our primary out-
come the (dichotomous) antidepressant response and not
the continuous outcomes (standardized mean differences
at endpoints). We did that on the basis that the concept of
response is useful to investigate the significance of the
results both from a statistical and a clinical point of view.
Antidepressant response has been extensively used as the
primary end point for defining improvement in many tri-
als [35,36]. The use of continuous measures has been crit-
icized because of its inability to discriminate between an
effect that is clinically insignificant versus an effect that is
clinically significant [37-39]. Other studies have used an
arbitrary three-point difference in the Hamilton Rating
Scale for Depression (equivalent to a standardized mean
difference of 0.5) as indicative of a clinically significant
change [40]. The few empirical studies, however, do not
support this threshold and point to larger effects that are
often observed in response rates [37]. We would like to
note however, that in our main comparison (SSRIs versus
placebo) we also carried out an analysis with the continu-
ous outcome and the result was not different. Fourth,
studies were generally small and most of them had a total
sample of less than 50 patients. Although in theory ran-
domization eliminates the problem of unknown con-
founding factors, an imbalance in the two arms cannot be
excluded given the small number of patients randomized.
These problems are more likely in the comparison
between SSRIs and TCAs as the total number of trials
Figure 5 Risk Ratio for dropouts of SSRIs vs Placebo in Parkinson's Disease Patients.Skapinakis et al. BMC Neurology 2010, 10:49
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included was smaller (three). Finally, in our main com-
parison, we selected to include two studies that were not
designed as typical placebo-controlled trials because we
considered that their inclusion could be justified for the
reasons we mentioned in the relevant section and in
order to minimize the possibility of type II errors. In any
case, exclusion of these studies did not alter our results.
Interpretation of the Results
Due to the small number of studies and the small sample
sizes we cannot exclude the possibility that the reported
lack of efficacy of SSRIs compared to placebo is a type II
error (i.e. a false negative result). If, however, there is a
true lack of effect what are the possible explanations?
First, it would be informative to compare the response
rates we found in our analysis with those reported from
general depression trials as the lack of efficacy could be
due to a low response rate of both SSRIs and placebo,
indicating a general lack of response in trials of depres-
sion in the context of PD. A meta-analysis that investi-
gated time trends of the placebo response rates in
antidepressant trials [41] reported an average response
rate for SSRIs of 48.9% (standard deviation: 10.3) while
the corresponding figure for placebo was 30% (standard
deviation: 8). Therefore, it seems that the lack of efficacy
of SSRIs in our analysis is probably due to a lower than
e xpected response rate for SSRIs (36% in our analysis)
while the response rates we found for placebo (34%) were
very close to those reported in the general depression lit-
erature. This observation does not support the view that
there is a general lack of response in depression trials of
PD patients, but rather that SSRIs fail to achieve a
response comparable to the one achieved in general
depression trials. Second, the findings could be explained
by measurement bias. It is known that assessing the diag-
nostic criteria and severity of depression in PD patients is
a difficult task due to several overlapping symptoms (psy-
chomotor changes, apathy, fatigue, insomnia, sleep disor-
ders, weight loss, cognitive dysfunction, social
withdrawal) [9,42]. It has been suggested that the depres-
sion diagnostic criteria should be modified to assess
depression more accurately in PD patients [43]. In addi-
tion, assessment of depressive symptoms in the context of
PD is usually done with a non-etiological and "inclusive"
approach, where the evaluator assesses all symptoms of
depression irrespectively of the possible etiology and
whether some of the symptoms are secondary to PD [43].
However, if these measurement issues were the reason
behind the relative lack of efficacy of SSRIs one would
also expect a lower placebo response compared to general
depression trials, and this was not found as explained
before. Third, selection bias could also explain our
results. RCTs usually exclude patients with the more
severe depression, but these patients are more likely to
respond to SSRIs [40]. Most trials have excluded subjects
with suicidal ideation or psychotic depression. In addi-
tion, most of the patients included in the trials had mod-
erate levels of depression although there were exceptions
[22,25]. Therefore we do not know whether inclusion of
patients with severe or very severe levels of depression
could influence the results in favor of the SSRIs. In any
case the results of the present analysis should not be gen-
eralized beyond the level of moderate severity of depres-
sion. Fourth, there is the possibility that treatment of
depression in the context of PD may require higher doses
of antidepressants compared to non-comorbid depres-
sion. Most studies included in the analysis have used typ-
ical doses and it is not known whether an increase in dose
(or duration of treatment) could improve the response
rates of SSRIs.
Further support for a relative inefficiency of SSRIs in
the treatment of depression comorbid with PD is coming
from neurobiological studies. There is strong evidence
that serotonin dysfunction plays a key role in the
pathophysiology of major depression [44]. However, this
refers to depression not comorbid with PD. Research that
has been specifically carried out in depressed patients
with PD does not support the serotonergic dysfunction in
this subgroup. A recent review of imaging studies in PD
concluded that there is very little evidence to support a
major role for serotonergic system in regulating depres-
sion in the context of PD [45]. In contrast there is strong
evidence for the role of both the noradrenergic [45] and
dopaminergic systems [46].
Conclusion
SSRIs are prescribed in depression more often than any
other class of antidepressants and this is also true for
depression in the context of PD [7]. In the U.S. survey of
the treatment of depression in PD [7], 63% of the antide-
pressant prescriptions were for SSRIs and 7% only for
TCA. Similar trends are expected in other countries. Our
results show that the current clinical practice is not sup-
ported by strong randomized evidence. There is still
uncertainty on the efficacy of SSRIs in depression in the
context of PD and clinicians should be aware of this
uncertainty. Based upon the results of our analysis we
cannot exclude the possibility that SSRIs in the future
may show evidence of effectiveness, especially for severe
or very severe depression. The small number of studies
does not also permit us to recommend TCAs routinely
and more placebo-controlled trials are needed. In addi-
tion it is not known whether tertiary amine TCAs that act
on both serotonin and noradrenaline are better than sec-
ondary amine TCAs that act predominantly on noradren-
aline. We should note however, that in two of the three
studies that we included in our SSRIs versus TCAs com-
parison the investigators preferred to use secondarySkapinakis et al. BMC Neurology 2010, 10:49
http://www.biomedcentral.com/1471-2377/10/49
Page 10 of 11
amines [22,26]. Given this uncertainty clinicians could
consider using secondary amine TCAs at least as often as
SSRIs.
There are implications for future research as well. The
role of other antidepressant drugs should be further
investigated, particularly those that act on noradrenaline
or dopamine. We know that a major randomized trial of
venlafaxine, a dual re-uptake inhibitor (SNRI) is currently
conducted in the US, comparing this drug with parox-
etine and placebo, but results are not expected before
2011 (see: http://www.clinicaltrials.gov/ct2/show/
NCT00086190). The role of other potentially interesting
drugs should also be explored. Mirtazapine, enhances
both serotonergic and adrenergic neurotransmission [47]
and a case series reported that it improved parkisonian
tremor [48]. No studies have been carried out however
for its use as an antidepressant in PD. Bupropion, is also a
licensed antidepressant which acts as a dopamine
reuptake inhibitor and its role in treating depression in
P D  c o u l d  b e  e x p l o r e d  f u r t h e r .  F i n a l l y ,  f u t u r e  s t u d i e s
should have a more pragmatic design and include
patients with more severe depression (including those
with suicidal ideation or psychotic symptoms) as this is a
group of patients that is commonly seen in clinical prac-
tice and could benefit more from antidepressant treat-
ment.
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